Received by email:
File: Prototype Redesign Final 11.9.17.pdf
890 West Pender Street, Suite 600 69 Longwood Avenue
Vancouver, British Columbia Hyannis Port, MA,02647 USA
Canada V6C 1J9 617-571-6006
778-998-5000 www.imaginmedical.com
CSE Symbol: IME NR-2017-IME - 22
OTC Pink Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchange: DPD2
IMAGIN'S i/BLUE IMAGING SYTEM PROTOTYPE REDESIGN BEGINS
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will
establish a new standard of care for urologists in detecting cancers and visualizing the
surgical field in minimally invasive surgery. The Company's initial focus is bladder cancer.
______________________________________________________________________
Vancouver, B.C. and Boston, MA, November 9, 2017 Imagin Medical (CSE: IME) (OTC PINK:
IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the "Company") announced today that Optel, Inc.,
the company's optical product-design firm, will begin the redesign of the i/Blue Imaging System
prototype for manufacturability and commercialization. The redesign will be concurrent with the
first in-human research study using the i/Blue prototype that is anticipated to begin shortly at the
University of Rochester Medical Center.
With its unique expertise in the manufacture and miniaturization of optical systems, Optel
integrates optics, mechanics, electronics, and software into user-friendly, cost-effective products.
Optel will work with Imagin to bring the alpha prototype of its state-of-the-art, optics-based i/Blue
Imaging System through three phases of development: proof of concept, functional unit, and the
redesigned verified unit ready for manufacturing.
The i/Blue system will be a mobile device, 70% smaller than the current prototype that can be
easily moved between operating rooms and physicians' offices. First proof-of-concept product
samples are expected to be available late in the calendar first quarter of 2018. The device will
be highly manufacturable and cost effective, with a modular design that will be the basic platform
for Imagin's i/Blue Imaging System to expand from bladder cancer detection to other minimally
invasive surgical procedures requiring improved visualization.
The i/Blue Imaging System is highly sensitive and is estimated to be greater than 100 times more
precise than currently available systems. It is expected to highlight cancer lesions and put the
cancer in context in less than 10 minutes, compared to the current standard of one hour. It is
anticipated this procedure will be more comprehensive, improve outcomes, and expand the
market. Early detection may reduce the recurrence of bladder cancer.
Jay Eastman, Optel's founder, received his B.S. and Ph.D. at The Institute of Optics at the
University of Rochester. He previously held positions as the Omega Laser System project
manager, and Director of the Laboratory of Laser Energetics (LLE), where development of the
i/Blue Imaging System alpha prototype was completed. Dr. Eastman commented, "Combining our
electronics design expertise with the fact that the i/Blue prototype was developed at Rochester's
LLE and will be tested in the operating rooms at the University of Rochester Medical Center will
greatly facilitate rapid product development."
Critical to Imagin Medical, Optel will ensure that the i/Blue Imaging System will be in compliance
with the requirements of the FDA, Good Manufacturing Practices (GMP), European medical
device standard ISO 13485, and other international compliance requirements.
"With the urology community looking for improved bladder-cancer detection, this is an exciting
time as the human research study begins and the product redesign is underway," said Jim
Hutchens, Imagin's President and CEO.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use
of endoscopes. The Company believes it will radically improve the way physicians detect cancer.
Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent
in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate.
Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging
technology is based upon improved optical designs and advanced light sensors. Learn more at
www.imaginmedical.com.
For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com
Information set forth in this news release contains forward-looking statements. These statements reflect
management's current estimates, beliefs, intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward-looking statements are inherently uncertain and that
actual performance may be affected by a number of material factors, many of which are beyond the
Company's control. Accordingly, actual and future events, conditions and results may differ materially
from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking
information. Specifically, there is no assurance the Company's imaging system will work in the manner
expected, except as required under applicable securities legislation; the Company undertakes no
obligation to publicly update or revise forward-looking information. The CSE has neither approved nor
disapproved the information contained herein and does not accept responsibility for the adequacy or
accuracy of this news release.
{00858280;1}
File: Prototype Redesign Final 11.9.17.docx
CSE Symbol: IME NR-2017-IME - 22
OTC Pink Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchange: DPD2
IMAGIN'S i/BLUE IMAGING SYTEM PROTOTYPE REDESIGN BEGINS
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care
---> for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company's i
--->nitial focus is bladder cancer.
______________________________________________________________________
Vancouver, B.C. and Boston, MA, November 9, 2017 - Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart
--->Symbol: DPD2) (the "Company") announced today that Optel, Inc., the company's optical product-design firm, will begin
--->the redesign of the i/Blue Imaging System prototype for manufacturability and commercialization. The redesign will be
--->concurrent with the first in-human research study using the i/Blue prototype that is anticipated to begin shortly at t
--->he University of Rochester Medical Center.
With its unique expertise in the manufacture and miniaturization of optical systems, Optel integrates optics, mechanic
--->s, electronics, and software into user-friendly, cost-effective products. Optel will work with Imagin to bring the al
--->pha prototype of its state-of-the-art, optics-based i/Blue Imaging System through three phases of development: proof
--->of concept, functional unit, and the redesigned verified unit ready for manufacturing.
The i/Blue system will be a mobile device, 70% smaller than the current prototype that can be easily moved between ope
--->rating rooms and physicians' offices. First proof-of-concept product samples are expected to be available late in the
---> calendar first quarter of 2018. The device will be highly manufacturable and cost effective, with a modular design th
--->at will be the basic platform for Imagin's i/Blue Imaging System to expand from bladder cancer detection to other mini
--->mally invasive surgical procedures requiring improved visualization.
The i/Blue Imaging System is highly sensitive and is estimated to be greater than 100 times more precise than currentl
--->y available systems. It is expected to highlight cancer lesions and put the cancer in context in less than 10 minutes,
---> compared to the current standard of one hour. It is anticipated this procedure will be more comprehensive, improve ou
--->tcomes, and expand the market. Early detection may reduce the recurrence of bladder cancer.
Jay Eastman, Optel's founder, received his B.S. and Ph.D. at The Institute of Optics at the University of Rochester.
--->He previously held positions as the Omega Laser System project manager, and Director of the Laboratory of Laser Energe
--->tics (LLE), where development of the i/Blue Imaging System alpha prototype was completed. Dr. Eastman commented, "Comb
--->ining our electronics design expertise with the fact that the i/Blue prototype was developed at Rochester's LLE and wi
--->ll be tested in the operating rooms at the University of Rochester Medical Center will greatly facilitate rapid produc
--->t development."
Critical to Imagin Medical, Optel will ensure that the i/Blue Imaging System will be in compliance with the requiremen
--->ts of the FDA, Good Manufacturing Practices (GMP), European medical device standard ISO 13485, and other international
---> compliance requirements.
"With the urology community looking for improved bladder-cancer detection, this is an exciting time as the human resea
--->rch study begins and the product redesign is underway," said Jim Hutchens, Imagin's President and CEO.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Co
--->mpany believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder c
--->ancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a gr
--->eater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive
---> imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical
--->.com.
For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com
Information set forth in this news release contains forward-looking statements. These statements reflect management's
--->current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company ca
--->utions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a n
--->umber of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, con
--->ditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implie
--->d in the forward-looking information. Specifically, there is no assurance the Company's imaging system will work in t
--->he manner expected, except as required under applicable securities legislation; the Company undertakes no obligation t
--->o publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information
--->contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
© 2024 Canjex Publishing Ltd. All rights reserved.